Page URL:

University of California win CRISPR patent battle in Europe

3 April 2017
Appeared in BioNews 895

The European Patent Office (EPO) has declared that it intends to grant a broad patent for the use of CRISPR technologies to the University of California, the University of Vienna and Dr Emmanuelle Charpentier of the Max-Planck Institute in Berlin.

The intellectual property has been hotly disputed between two groups, one led by the University of California and the other by the Broad Institute in Massachusetts. The Broad group – who prevailed in the recent US patent dispute (see BioNews 889) – filed several Third Party Observations (TPOs) objecting to the grant, but the EPO did not agree with their arguments. The Broad group now have nine months to file any further objections before the patent is issued.

'We're very pleased with the decision by the European Patent Office recognising the broad applicability of our foundational IP, and we look forward to pursuing additional cases to grant in other jurisdictions globally,' said Rodger Novak, CEO of CRISPR Therapeutics, part of the University of California group.

The University of California group's claim is founded on the work of Professor Jennifer Doudna, Dr Emmanuelle Charpentier and their team at UC Berkeley, who were first to modify the CRISPR system found naturally in bacteria and used it to cut DNA in a test tube.

The opposing group comprises the Broad Institute, Harvard University, MIT, Wageningen University, the University of Iowa, and the University of Tokyo. Their claim is based around the work of Professor Feng Zhang and colleagues, who were first to get the technology working in the more complex eukaryotic cells found in plants, animals and humans.

The US Patents and Trademarks Office (USPTO) previously granted 12 patents for the use of CRISPR in eukaryotic cells to the Broad Institute, but Europe and the US have different ways of deciding who to award a patent to. Europe gives priority to the first party to file a patent claim, whereas until recently, the US system used a first party to invent policy, under which the US patent dispute was heard.

Eric Rhodes, CEO of ERS Genomics (part of the UC group), said: 'I hope this decision by the EPO provides even more clarity for those looking to utilise the technology. At ERS, we are hopeful that we can expect similar outcomes throughout the roughly 80 countries that use a first-to-file system like Europe.'

The Broad Institute stresses that the EPO process 'may involve adjusting patent claims after a patent has been issued, in response to oppositions… adjustments may be required in this case'.

18 June 2018 - by Dr Sam Sherratt 
The US Patent and Trademark Office has decided to grant two new CRISPR patents to the University of California, Berkeley...
4 June 2018 - by Jen Willows 
Three scientists will share the US$1 million 2018 Kavli prize in Nanoscience 'for the invention of CRISPR-Cas9, a precise nanotool for editing DNA, causing a revolution in biology, agriculture, and medicine'...
14 August 2017 - by Ryan Ross 
German-based company MilliporeSigma has announced that the European Patent Office intends to approve its CRISPR patent for use in eukaryotic cells...
31 July 2017 - by Dr Rachel Montgomery 
The University of California has moved to appeal a decision of the US Patent Trial and Appeal Board over the use of CRISPR in eukaryotic cells...
17 July 2017 - by Kulraj Singh Bhangra 
The Broad Institute of Massachusetts Institute of Technology and Harvard will take part in an initiative to simplify licensing CRISPR genome editing technology to other organisations and institutions...
13 March 2017 - by Dr Katie Howe 
Chinese scientists have successfully used genome editing to correct mutations in viable human embryos for the first time...
20 February 2017 - by Ryan Ross 
The US Patent and Trademark Office has upheld the right of the Broad Institute of MIT and Harvard to the genome-editing tool CRISPR/Cas9...
12 December 2016 - by Antony Starza-Allen 
Oral arguments from lawyers acting for the Broad Institute and the University of California, Berkeley, in the high-profile CRISPR/Cas9 patent dispute have been heard in Virginia...
3 October 2016 - by Dr Helen Robertson 
Two teams of researchers have used CRISPR genome editing technology to identify 'non-coding' regions of the genome for the first time...
26 September 2016 - by Anneesa Amjad 
A scientist in Sweden has become the first to edit genes in healthy human embryos...
to add a Comment.

By posting a comment you agree to abide by the BioNews terms and conditions

Syndicate this story - click here to enquire about using this story.